Scrip
Lilly issues "Dear Doctor" letter over risks of Zyprexa in adolescents
02 February 2010
Katie McQue
Please Login to read the full article.
02 February 2010
Katie McQue
katie.mcque@informa.com
Lilly has issued a "Dear Doctor" letter regarding the use of its atypical antipsychotic Zyprexa (olanzapine) in adolescents to warn of the increased risk of weight gain and hyperlipidemia compared with its use in adults.
Zyprexa, a dopamine, serotonin and muscarinic receptor antagonist,...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Alarming rise in chronic use of meds by American children, Medco report says
- Lurasidone filed for schizophrenia in the US
- Seroquel collects more approvals, and a complete response letter, from the US FDA
- AstraZeneca finalises $520 million settlement in Seroquel off-label probe
ANALYSIS
- Executive Briefing – Brazil emerges as a saviour for pharma
- Executive Briefing – Health technology assessment: a brief look at the EU
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
